Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Timolol for Cutaneous Telangiectasias in HHT
NCT01752049Phase 2
Key facts
- Status
- Completed
- Start
- May 2013
- Primary completion
- Aug 2019
- Countries
- 1
- Sponsor
- Unity Health Toronto
- Modality
- Small Molecules
- Drugs
- Timacor
- Conditions
- hereditary hemorrhagic telangiectasia (HHT)
01
Overview
Phase 2, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) comparing Topical timolol maleate with Placebo (2 arms). Primary endpoint: Change in Lesion Area of Treated Telangiectasia at 84 days. Started May 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Topical timolol maleate
Application of Apo-Timop 0.5% drops to 3 telangiectasias
Placebo
Application of placebo saline drops to 1 telangiectasia
03
Endpoints
Primary
Change in Lesion Area of Treated Telangiectasia
Secondary
Descriptive Changes in Histopathology in Baseline vs Treated Lesions
Serum Angiogenic Markers
Stability of Area of Untreated Telangiectasias Over the 84 Day Period
Blood Flow Velocity and Volume Flow Rates
Beyond the preview
Go deeper on NCT01752049.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01752049.